Phase 2 Trial of Oral Treatment for Ulcerative Colitis Now Recruiting

Phase 2 Trial of Oral Treatment for Ulcerative Colitis Now Recruiting
Lycera has announced the launch of a Phase 2 clinical trial to assess the effectiveness of its lead clinical-stage candidate, LYC-30937-EC (Enteric Coated), as a once daily oral treatment for patients with active ulcerative colitis (UC). The clinical trial is currently recruiting participants. “The initiation of the Phase 2 clinical trial of LYC-30937-EC is an important milestone in Lycera’s continued progress and is one of several clinical studies we plan to initiate in the second half of 2016 as we build our portfolio of novel immune modulatory treatments,” Paul Sekhri, Lycera’s president and chief executive officer, said in a
Subscribe or to access all post and page content.